Living Donor Liver Transplantation for Hepatocellular Carcinoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-09-01

AUTHORS

Sung-Gyu Lee , Deok-Bog Moon

ABSTRACT

Liver transplantation (LT) may be the best curative treatment that offers a chance of cure for the tumor and the underlying cirrhosis by complete extirpation of both. In Asia, where the supply of cadaveric grafts remains scarce and the incidence of HCC combined with chronic hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related liver disease is high, adult living donor liver transplantation (LDLT) has been settled upon as a practical alternative to deceased-donor liver transplantation (DDLT). Even in Western countries, where adequate access to DDLT is feasible for HCC patients satisfying the Milan criteria, the necessity for LDLT is well established in particular for more advanced HCC patients who are disadvantaged by current allocation algorithms for grafts from deceased donors due to organ shortage, increasing waiting lists, and the expectation that many patients listed for LT will die while awaiting a suitable organ. In the field of LDLT in Asia, numerous technical innovations were achieved to secure donor safety, as well as to ensure patient survival. The experience with LDLT for HCC has been progressively increasing in many Asian countries to date. Although there are questions regarding the higher recurrence of HCC after LDLT than after DDLT, the application of the Milan and UCSF criteria to LDLT in high-volume multicenter cohorts from Japan and Korea has resulted in patient survival outcomes very similar to those following DDLT. Recently, inclusion of biologic tumor markers such as alpha fetoprotein (AFP), protein induced by vitamin K antagonist II (PIVKA II), and positive positron emission tomography (PET) in addition to parameters of tumor morphology might be the key to establishing the best criteria for LDLT for HCC. As pretransplant treatments, most LDLT centers in Asia cannot adopt the strategy of bridging therapy under scarcity of cadaveric organ donation but have to use those multi-modality treatments as a salvage intending for primary curative treatment or a downstaging therapy before LDLT. After LDLT, basically there is no difference in the management strategy for HCC recurrence between DDLD and LDLT. More... »

PAGES

165-179

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-16037-0_11

DOI

http://dx.doi.org/10.1007/978-3-642-16037-0_11

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004015524

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22941020


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Living Donors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "North America", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue and Organ Procurement", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Waiting Lists", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, 138-736, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.413967.e", 
          "name": [
            "Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, 138-736, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Sung-Gyu", 
        "id": "sg:person.01141712025.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141712025.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, 138-736, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.413967.e", 
          "name": [
            "Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, 138-736, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moon", 
        "givenName": "Deok-Bog", 
        "id": "sg:person.0752624137.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752624137.23"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-09-01", 
    "datePublishedReg": "2012-09-01", 
    "description": "Liver transplantation (LT) may be the best curative treatment that offers a chance of cure for the tumor and the underlying cirrhosis by complete extirpation of both. In Asia, where the supply of cadaveric grafts remains scarce and the incidence of HCC combined with chronic hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related liver disease is high, adult living donor liver transplantation (LDLT) has been settled upon as a practical alternative to deceased-donor liver transplantation (DDLT). Even in Western countries, where adequate access to DDLT is feasible for HCC patients satisfying the Milan criteria, the necessity for LDLT is well established in particular for more advanced HCC patients who are disadvantaged by current allocation algorithms for grafts from deceased donors due to organ shortage, increasing waiting lists, and the expectation that many patients listed for LT will die while awaiting a suitable organ. In the field of LDLT in Asia, numerous technical innovations were achieved to secure donor safety, as well as to ensure patient survival. The experience with LDLT for HCC has been progressively increasing in many Asian countries to date. Although there are questions regarding the higher recurrence of HCC after LDLT than after DDLT, the application of the Milan and UCSF criteria to LDLT in high-volume multicenter cohorts from Japan and Korea has resulted in patient survival outcomes very similar to those following DDLT. Recently, inclusion of biologic tumor markers such as alpha fetoprotein (AFP), protein induced by vitamin K antagonist II (PIVKA II), and positive positron emission tomography (PET) in addition to parameters of tumor morphology might be the key to establishing the best criteria for LDLT for HCC. As pretransplant treatments, most LDLT centers in Asia cannot adopt the strategy of bridging therapy under scarcity of cadaveric organ donation but have to use those multi-modality treatments as a salvage intending for primary curative treatment or a downstaging therapy before LDLT. After LDLT, basically there is no difference in the management strategy for HCC recurrence between DDLD and LDLT.", 
    "editor": [
      {
        "familyName": "Vauthey", 
        "givenName": "Jean-Nicolas", 
        "type": "Person"
      }, 
      {
        "familyName": "Brouquet", 
        "givenName": "Antoine", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-16037-0_11", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-16036-3", 
        "978-3-642-16037-0"
      ], 
      "name": "Multidisciplinary Treatment of Hepatocellular Carcinoma", 
      "type": "Book"
    }, 
    "keywords": [
      "deceased-donor liver transplantation", 
      "positive positron emission tomography", 
      "donor liver transplantation", 
      "liver transplantation", 
      "curative treatment", 
      "HCC patients", 
      "alpha fetoprotein", 
      "chronic hepatitis B virus", 
      "vitamin K antagonist II", 
      "multi-modality treatment", 
      "incidence of HCC", 
      "field of LDLT", 
      "biologic tumor markers", 
      "primary curative treatment", 
      "advanced HCC patients", 
      "chance of cure", 
      "hepatitis C virus", 
      "hepatitis B virus", 
      "patient survival outcomes", 
      "current allocation algorithm", 
      "positron emission tomography", 
      "cadaveric organ donation", 
      "underlying cirrhosis", 
      "Milan criteria", 
      "UCSF criteria", 
      "cadaveric grafts", 
      "multicenter cohort", 
      "pretransplant treatment", 
      "HCC recurrence", 
      "deceased donors", 
      "liver disease", 
      "donor safety", 
      "patient survival", 
      "survival outcomes", 
      "B virus", 
      "LDLT", 
      "high recurrence", 
      "tumor markers", 
      "hepatocellular carcinoma", 
      "organ shortage", 
      "suitable organs", 
      "transplantation", 
      "emission tomography", 
      "antagonist II", 
      "tumor morphology", 
      "complete extirpation", 
      "patients", 
      "organ donation", 
      "HCC", 
      "recurrence", 
      "treatment", 
      "graft", 
      "therapy", 
      "Western countries", 
      "adequate access", 
      "numerous technical innovations", 
      "virus", 
      "cirrhosis", 
      "HBV", 
      "carcinoma", 
      "cohort", 
      "tumors", 
      "salvage", 
      "incidence", 
      "disease", 
      "criteria", 
      "fetoprotein", 
      "cure", 
      "tomography", 
      "survival", 
      "outcomes", 
      "adults", 
      "organs", 
      "management strategies", 
      "Asian countries", 
      "markers", 
      "safety", 
      "extirpation", 
      "good criterion", 
      "practical alternative", 
      "donation", 
      "donors", 
      "differences", 
      "strategies", 
      "center", 
      "chance", 
      "protein", 
      "countries", 
      "date", 
      "DDLD", 
      "Milan", 
      "experience", 
      "addition", 
      "list", 
      "access", 
      "inclusion", 
      "Asia", 
      "alternative", 
      "Japan", 
      "shortage", 
      "technical innovations", 
      "Korea", 
      "necessity", 
      "questions", 
      "supply", 
      "morphology", 
      "expectations", 
      "parameters", 
      "scarcity", 
      "key", 
      "applications", 
      "field", 
      "innovation", 
      "algorithm", 
      "allocation algorithm", 
      "C virus", 
      "high-volume multicenter cohorts", 
      "K antagonist II", 
      "most LDLT centers", 
      "LDLT centers"
    ], 
    "name": "Living Donor Liver Transplantation for Hepatocellular Carcinoma", 
    "pagination": "165-179", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004015524"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-16037-0_11"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22941020"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-16037-0_11", 
      "https://app.dimensions.ai/details/publication/pub.1004015524"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-12-01T20:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/chapter/chapter_245.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-16037-0_11"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-16037-0_11'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-16037-0_11'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-16037-0_11'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-16037-0_11'


 

This table displays all metadata directly associated to this object as RDF triples.

256 TRIPLES      23 PREDICATES      161 URIs      154 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-16037-0_11 schema:about N5378b6c840264fd9a8d58ed29520460e
2 N5b9efb5435254b5488966b74a6d3d253
3 N61a0fc07d92a4f8fbe8aa00da4b6c8a3
4 N74f703cb4b814d8cb0d279456df2e572
5 N784e7f4f48bb4f7296eb4fb6edc76787
6 N9b60cb969f46462d8bf40624dabbc24c
7 Nafc6505df76641eb9b41eccde017e645
8 Nb86dc1f9db8e4f26a7c048cfa74863ea
9 Nbbb281b4e77c4c409d05a4eea877061b
10 Nc896abae64b240b79f5d1a163ccfe09e
11 Ncb60c5467036488e9b8534126f6d99ac
12 Nccf2a41462454d34868d5ab462a16a76
13 Ncffe7b8430f046da839e7d5180bdcb16
14 Ne78cc271457a4b39acecc65cbc121125
15 Nf488afeb00424f259a06551b34a5b881
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Na0fb162259074cb39a5d6f2cd7721799
19 schema:datePublished 2012-09-01
20 schema:datePublishedReg 2012-09-01
21 schema:description Liver transplantation (LT) may be the best curative treatment that offers a chance of cure for the tumor and the underlying cirrhosis by complete extirpation of both. In Asia, where the supply of cadaveric grafts remains scarce and the incidence of HCC combined with chronic hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related liver disease is high, adult living donor liver transplantation (LDLT) has been settled upon as a practical alternative to deceased-donor liver transplantation (DDLT). Even in Western countries, where adequate access to DDLT is feasible for HCC patients satisfying the Milan criteria, the necessity for LDLT is well established in particular for more advanced HCC patients who are disadvantaged by current allocation algorithms for grafts from deceased donors due to organ shortage, increasing waiting lists, and the expectation that many patients listed for LT will die while awaiting a suitable organ. In the field of LDLT in Asia, numerous technical innovations were achieved to secure donor safety, as well as to ensure patient survival. The experience with LDLT for HCC has been progressively increasing in many Asian countries to date. Although there are questions regarding the higher recurrence of HCC after LDLT than after DDLT, the application of the Milan and UCSF criteria to LDLT in high-volume multicenter cohorts from Japan and Korea has resulted in patient survival outcomes very similar to those following DDLT. Recently, inclusion of biologic tumor markers such as alpha fetoprotein (AFP), protein induced by vitamin K antagonist II (PIVKA II), and positive positron emission tomography (PET) in addition to parameters of tumor morphology might be the key to establishing the best criteria for LDLT for HCC. As pretransplant treatments, most LDLT centers in Asia cannot adopt the strategy of bridging therapy under scarcity of cadaveric organ donation but have to use those multi-modality treatments as a salvage intending for primary curative treatment or a downstaging therapy before LDLT. After LDLT, basically there is no difference in the management strategy for HCC recurrence between DDLD and LDLT.
22 schema:editor Nb4ceb1607dcc40f7af2c2301af3cc747
23 schema:genre chapter
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf Nc2ab3a1ffa7242b88d3dae34ab213ffb
27 schema:keywords Asia
28 Asian countries
29 B virus
30 C virus
31 DDLD
32 HBV
33 HCC
34 HCC patients
35 HCC recurrence
36 Japan
37 K antagonist II
38 Korea
39 LDLT
40 LDLT centers
41 Milan
42 Milan criteria
43 UCSF criteria
44 Western countries
45 access
46 addition
47 adequate access
48 adults
49 advanced HCC patients
50 algorithm
51 allocation algorithm
52 alpha fetoprotein
53 alternative
54 antagonist II
55 applications
56 biologic tumor markers
57 cadaveric grafts
58 cadaveric organ donation
59 carcinoma
60 center
61 chance
62 chance of cure
63 chronic hepatitis B virus
64 cirrhosis
65 cohort
66 complete extirpation
67 countries
68 criteria
69 curative treatment
70 cure
71 current allocation algorithm
72 date
73 deceased donors
74 deceased-donor liver transplantation
75 differences
76 disease
77 donation
78 donor liver transplantation
79 donor safety
80 donors
81 emission tomography
82 expectations
83 experience
84 extirpation
85 fetoprotein
86 field
87 field of LDLT
88 good criterion
89 graft
90 hepatitis B virus
91 hepatitis C virus
92 hepatocellular carcinoma
93 high recurrence
94 high-volume multicenter cohorts
95 incidence
96 incidence of HCC
97 inclusion
98 innovation
99 key
100 list
101 liver disease
102 liver transplantation
103 management strategies
104 markers
105 morphology
106 most LDLT centers
107 multi-modality treatment
108 multicenter cohort
109 necessity
110 numerous technical innovations
111 organ donation
112 organ shortage
113 organs
114 outcomes
115 parameters
116 patient survival
117 patient survival outcomes
118 patients
119 positive positron emission tomography
120 positron emission tomography
121 practical alternative
122 pretransplant treatment
123 primary curative treatment
124 protein
125 questions
126 recurrence
127 safety
128 salvage
129 scarcity
130 shortage
131 strategies
132 suitable organs
133 supply
134 survival
135 survival outcomes
136 technical innovations
137 therapy
138 tomography
139 transplantation
140 treatment
141 tumor markers
142 tumor morphology
143 tumors
144 underlying cirrhosis
145 virus
146 vitamin K antagonist II
147 schema:name Living Donor Liver Transplantation for Hepatocellular Carcinoma
148 schema:pagination 165-179
149 schema:productId N050bdf2a12df4b4aa6759cdd634b6d4b
150 N9ae90c09c34f4156bf2fde2cea5a0f16
151 Nc3eed45c88c4488e87445325ebc6fe57
152 schema:publisher N456a298f9b2b424ea44216f43aca43cc
153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004015524
154 https://doi.org/10.1007/978-3-642-16037-0_11
155 schema:sdDatePublished 2021-12-01T20:01
156 schema:sdLicense https://scigraph.springernature.com/explorer/license/
157 schema:sdPublisher Ncdfa31856ab4461a915d530eaa8b258a
158 schema:url https://doi.org/10.1007/978-3-642-16037-0_11
159 sgo:license sg:explorer/license/
160 sgo:sdDataset chapters
161 rdf:type schema:Chapter
162 N050bdf2a12df4b4aa6759cdd634b6d4b schema:name pubmed_id
163 schema:value 22941020
164 rdf:type schema:PropertyValue
165 N1222ba5066364ad08539a99ea6ec392c schema:familyName Brouquet
166 schema:givenName Antoine
167 rdf:type schema:Person
168 N1be71b6eefd54f38828bda25bb5bfb5c rdf:first sg:person.0752624137.23
169 rdf:rest rdf:nil
170 N456a298f9b2b424ea44216f43aca43cc schema:name Springer Nature
171 rdf:type schema:Organisation
172 N5378b6c840264fd9a8d58ed29520460e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Humans
174 rdf:type schema:DefinedTerm
175 N5b9efb5435254b5488966b74a6d3d253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Waiting Lists
177 rdf:type schema:DefinedTerm
178 N61a0fc07d92a4f8fbe8aa00da4b6c8a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name North America
180 rdf:type schema:DefinedTerm
181 N74f703cb4b814d8cb0d279456df2e572 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Treatment Outcome
183 rdf:type schema:DefinedTerm
184 N784e7f4f48bb4f7296eb4fb6edc76787 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Liver Transplantation
186 rdf:type schema:DefinedTerm
187 N871f2fe7a63a45429379a4d8b70101e8 rdf:first N1222ba5066364ad08539a99ea6ec392c
188 rdf:rest rdf:nil
189 N9ae90c09c34f4156bf2fde2cea5a0f16 schema:name dimensions_id
190 schema:value pub.1004015524
191 rdf:type schema:PropertyValue
192 N9b60cb969f46462d8bf40624dabbc24c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Living Donors
194 rdf:type schema:DefinedTerm
195 Na0fb162259074cb39a5d6f2cd7721799 rdf:first sg:person.01141712025.28
196 rdf:rest N1be71b6eefd54f38828bda25bb5bfb5c
197 Nafc6505df76641eb9b41eccde017e645 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Hepatitis C
199 rdf:type schema:DefinedTerm
200 Nb4ceb1607dcc40f7af2c2301af3cc747 rdf:first Nbc5eacde479542f0a3ed670bcb94e33b
201 rdf:rest N871f2fe7a63a45429379a4d8b70101e8
202 Nb86dc1f9db8e4f26a7c048cfa74863ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Tissue and Organ Procurement
204 rdf:type schema:DefinedTerm
205 Nbbb281b4e77c4c409d05a4eea877061b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Liver Neoplasms
207 rdf:type schema:DefinedTerm
208 Nbc5eacde479542f0a3ed670bcb94e33b schema:familyName Vauthey
209 schema:givenName Jean-Nicolas
210 rdf:type schema:Person
211 Nc2ab3a1ffa7242b88d3dae34ab213ffb schema:isbn 978-3-642-16036-3
212 978-3-642-16037-0
213 schema:name Multidisciplinary Treatment of Hepatocellular Carcinoma
214 rdf:type schema:Book
215 Nc3eed45c88c4488e87445325ebc6fe57 schema:name doi
216 schema:value 10.1007/978-3-642-16037-0_11
217 rdf:type schema:PropertyValue
218 Nc896abae64b240b79f5d1a163ccfe09e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Severity of Illness Index
220 rdf:type schema:DefinedTerm
221 Ncb60c5467036488e9b8534126f6d99ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Hepatitis B
223 rdf:type schema:DefinedTerm
224 Nccf2a41462454d34868d5ab462a16a76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Patient Selection
226 rdf:type schema:DefinedTerm
227 Ncdfa31856ab4461a915d530eaa8b258a schema:name Springer Nature - SN SciGraph project
228 rdf:type schema:Organization
229 Ncffe7b8430f046da839e7d5180bdcb16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Immunosuppression
231 rdf:type schema:DefinedTerm
232 Ne78cc271457a4b39acecc65cbc121125 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
233 schema:name Carcinoma, Hepatocellular
234 rdf:type schema:DefinedTerm
235 Nf488afeb00424f259a06551b34a5b881 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
236 schema:name Neoplasm Recurrence, Local
237 rdf:type schema:DefinedTerm
238 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
239 schema:name Medical and Health Sciences
240 rdf:type schema:DefinedTerm
241 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
242 schema:name Clinical Sciences
243 rdf:type schema:DefinedTerm
244 sg:person.01141712025.28 schema:affiliation grid-institutes:grid.413967.e
245 schema:familyName Lee
246 schema:givenName Sung-Gyu
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141712025.28
248 rdf:type schema:Person
249 sg:person.0752624137.23 schema:affiliation grid-institutes:grid.413967.e
250 schema:familyName Moon
251 schema:givenName Deok-Bog
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752624137.23
253 rdf:type schema:Person
254 grid-institutes:grid.413967.e schema:alternateName Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, 138-736, Seoul, Korea
255 schema:name Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, 138-736, Seoul, Korea
256 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...